Orifarm and NNIT have signed a contract for the delivery of end-to-end IT services in connection with Orifarm’s acquisition of a significant portfolio of select over-the-counter (OTC) and prescription pharmaceutical products from Japanese pharmaceutical giant Takeda.
The contract involves IT services prior to, during and after the acquisition and relates to preparing and assisting Orifarm in taking over the IT environment that is part of the acquisition. Once the Takeda acquisition is formalised, NNIT will be managing applications and related infrastructure as part of a multi-year outsourcing agreement. The contract will run for up to five years and represents a large DKK double-digit million amount.
‘NNIT has a strong history of excellence as IT provider to the Life Sciences industry, and we feel confident that we have chosen the right partner to support this next step in the Orifarm journey. A number of NNIT consultants already have expert knowledge of the IT environment we’re acquiring, so we’re in very good hands,’ says Klaus Mortensen, Vice President, Corporate IT, Orifarm.
‘We are extremely pleased to be Orifarm’s new strategic IT partner. With the acquisition of the portfolio from Takeda, Orifarm adds another dimension to its business and evolves into a company with a significant focus on pharmaceutical production. This makes Orifarm a perfect match with NNIT’s Life Sciences focus. NNIT has a proven record of successfully working with regulated life sciences customers, and we are excited to support Orifarm on their journey,’ says Flemming Kjøller, Vice President, Global Sales – Life Sciences, NNIT.
Orifarm Group is the largest parallel importer of pharmaceuticals in Europe and the largest supplier of pharmaceuticals in Denmark. The Group comprises a number of companies engaged in the import, production, repackaging, distribution, registration, and sales of pharmaceuticals. The Group is engaged in parallel importing of pharmaceuticals from EU countries, which are sold in Denmark, Norway, Sweden, Finland, Germany, Holland, Austria, UK, and Belgium.
Additionally, the Group is engaged in the sales of generic pharmaceuticals in the Nordic countries. A generic drug contains the same active ingredients as the original drug. The active ingredients are, however, no longer patented, and the generic drug can therefore be produced and sold at a lower price than the corresponding original.
Today, Orifarm has around 1,200 employees and expect to have around 1,900 employees after the integration of the acquisition from Takeda. Together they make a mark in business and society; bringing digital transformation to life. The NNIT Group provides a wide range of IT and consulting services to the world.
Supporting the entire supply chain, we help optimise internal company processes, production and sales as well as delivery to customers. They are experts in supporting the world’s most regulated industries subject to strict governance of processes, quality and data management and documentation and in guiding them on their digital journey.
The Group consists of group company NNIT A/S and the subsidiaries Valiance, SCALES and Excellis Health Solutions. Together, these companies employ over 3,000 people, primarily in Europe, Asia and the US. In Denmark, where the Group HQ is based, they are one of the leading IT consultancies, servicing both private and public sector customers across all industries. In the rest of Europe, US and Asia, they are solely focused on companies within life sciences.